Russia has reported an encouraging development in its experimental cancer treatment programme, after the first patient to complete treatment with its personalised messenger RNA (mRNA) cancer vaccine reportedly showed no detectable cancer metastases four months after completing therapy.
The development was announced by Alexander Gintsburg, scientific director of Russia’s Gamaleya National Research Centre for Epidemiology and Microbiology, which collaborated with the National Medical Research Radiological Centre to develop the vaccine known as NeoOncovac.
According to Gintsburg, the patient, a 60-year-old man diagnosed with stage-three melanoma, has completed the treatment programme and is undergoing regular medical examinations.
He said doctors had not detected any new tumours during four months of observation, while previously identified metastases were no longer detectable.
The patient is expected to remain under medical supervision for approximately three years, with monthly examinations, including computed tomography (CT) scans, to monitor his condition and check for possible recurrence.
The development has generated interest in the international medical community, although researchers have cautioned that longer observation and further studies are necessary before the treatment’s effectiveness can be conclusively established.
How The Russian Cancer Vaccine Works
Unlike conventional vaccines designed to prevent infectious diseases, NeoOncovac is a therapeutic vaccine developed to help the body’s immune system identify and attack cancer cells.
The treatment uses messenger RNA technology and is customised for individual patients based on the genetic characteristics of their tumours.
Scientists analyse samples of a patient’s tumour and identify specific molecular features, known as tumour antigens, that distinguish cancer cells from healthy cells.
They then use the information to develop an individualised vaccine containing instructions intended to stimulate the immune system to recognise and destroy cancer cells carrying those markers.
The approach is designed to equip the body’s immune defences to identify malignant cells, including microscopic cancer deposits that may remain after surgery or spread to other parts of the body.
Russia’s National Medical Research Radiological Centre announced in November 2025 that the vaccine had received approval for clinical use, initially for adults with inoperable or metastatic cutaneous melanoma.
The treatment is intended to be administered alongside other immunotherapy drugs in eligible patients, while another approved application covers patients who have undergone surgery to remove metastatic melanoma lesions.
Six Patients Have Received The Treatment
Gintsburg disclosed that six melanoma patients had received the personalised vaccine as of November 12, 2026.
While the first patient has completed treatment, a second patient is about halfway through the programme, with four others also having commenced treatment.
The Russian authorities are targeting 20 patients at the Herzen Moscow Research Institute of Oncology by the end of 2026.
The government has also reportedly allocated funding for the treatment and follow-up monitoring of 120 patients during 2026 and 2027.
According to Gintsburg, approximately seven million Russian roubles has been allocated for the production of an individual vaccine and the complete treatment course for each patient.
The treatment programme involves up to 10 administrations, with the vaccine manufactured individually using the genetic profile of each patient’s tumour.
Not Yet A Cure For Cancer
Despite the encouraging report, medical experts warn against interpreting the development as evidence that Russia has discovered a universal cure for cancer.
The disappearance of detectable metastases in one patient is a positive early outcome, but it does not establish that the disease has been permanently eliminated.
Researchers still need to determine whether the patient will remain cancer-free over a longer period, how many other patients will respond positively and whether the treatment can produce similar outcomes in larger groups.
There are also questions about its long-term safety, effectiveness and possible application to other forms of cancer.
For now, NeoOncovac’s authorised application is limited to specific cases of cutaneous melanoma. It is not an approved treatment for every type of cancer.
Global Race For Personalised Cancer Vaccines
Russia is not alone in exploring mRNA technology as a weapon against cancer.
Pharmaceutical companies Moderna and Merck in the United States are also developing a personalised mRNA cancer vaccine designed to work alongside the immunotherapy drug Keytruda.
Results from a major Phase III trial involving more than 1,100 patients with high-risk melanoma, published in October 2026, showed that the combination reduced the risk of cancer recurrence or death by 42 per cent compared with Keytruda alone.
The findings provide further evidence of the growing potential of personalised cancer vaccines, although researchers continue to monitor patients to establish their long-term benefits.
For cancer patients around the world, including in Nigeria, these developments offer fresh possibilities in the search for more effective treatments.
However, specialists caution that patients should not abandon established cancer treatment or travel for unverified therapies based on claims of a guaranteed cure.
Russia’s reported results represent an encouraging development in personalised cancer treatment. Whether NeoOncovac will eventually become a widely effective weapon against melanoma and other cancers will depend on the outcome of further clinical experience and long-term medical monitoring.
Credit: GWG
